New Insights into Diagnosis and Treatment of Prostate Cancer and Urological Epidemiology

Dear Colleagues,

Prostate cancer is the second most commonly diagnosed cancer in men. Patients with localized prostate cancer mostly undergo definitive curative therapy with surgery or radiation, followed by monitoring of prostate-specific antigen (PSA). However, approximately 30% of patients who undergo definitive treatment will have disease relapse. Androgen-deprivation therapy has been the mainstay of treatment for advanced prostate cancer and usually induces disease regression commonly defined by PSA declines, radiographic responses, and clinical improvement. Unfortunately, many of these patients will continue to experience PSA rise or biochemical recurrence. Over time, castration-resistant prostate cancer (CRPC) cells emerge. CRPC is a heterogeneous disease state that ranges from the serologic progression of disease-only with no radiographic or clinical evidence of metastasis to evidence of metastasis and significant debilitating symptoms from disease progression. Therefore, there is an unmet need to identify new reliable markers, new non-invasive diagnostic approaches, new therapeutic targets, and novel drugs with appropriate treatment therapies to delay and/or overcome the development of CRPC, which results in cancer metastasis.

Apart from urological oncology, non-malignant urological conditions are highly prevalent but not often highly prioritized for investigation in the context of multiple chronic conditions, particularly due to a perception of a lack of rigorous, quality outcome studies. Although these conditions frequently affect patient quality of life, their effect on other patient outcomes has been less well characterized. Symptoms commonly attributed to non-malignant urologic conditions can often be caused by other conditions and, therefore, standard diagnostic codes have poor accuracy for capturing benign urologic disease burden compared to other medical specialties. This underscores the importance of developing new sources and methods of inquiry in this area.

In light of these new advancements and needs, the Journal of Clinical Medicine has launched a Special Issue on advancements in the diagnosis and treatment of prostate cancer and urological epidemiology. We are prioritizing high-quality original studies, but also welcome well-designed meta-analyses and well reviews. We look forward to your contribution.

Prof. Piotr Chlosta
Dr. Mikolaj Przydacz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.